sohB Antibody

What is the sohB protein and why is it significant in research?

The sohB gene encodes a previously undiscovered periplasmic protease in E. coli that, when overexpressed, can partially compensate for the missing HtrA protein function. The sohB gene maps to 28 min on the E. coli chromosome, precisely between the topA and btuR genes. The gene encodes a 39,000-Mr precursor protein which is processed to a 37,000-Mr mature form with a predicted signal sequence cleavage site between amino acids 22 and 23 . This protease is significant because it represents an important component of bacterial stress response and protein quality control mechanisms, particularly at high temperatures (above 39°C).

How is the sohB antibody typically produced for research applications?

Production of antibodies against bacterial proteins like sohB typically involves:

• Antigen preparation: Purification of recombinant sohB protein or selection of antigenic peptides from the mature protein sequence

• Immunization protocols: Utilizing animal models (typically rabbits or mice) with purified antigen

• Alternative approaches: In vitro methods including phage display or yeast display technologies

• Antibody format selection: Choosing between full-length antibodies (IgG) or fragments like scFvs (single chain fragment variable) depending on the application requirements

• Validation: Confirming specificity through Western blotting, ELISA, and immunofluorescence techniques

For high-throughput applications, computational approaches using deep learning models can be employed to generate antibody variable region sequences with desirable properties, as demonstrated by recent research utilizing generative adversarial networks .

What antibody formats are most suitable for detecting bacterial periplasmic proteins like sohB?

The choice of antibody format depends on research objectives and constraints:

Single chain fragment variable (scFv) formats may be particularly advantageous for periplasmic targets as they comprise only the variable regions of the light chain (VL) and heavy chain (VH) linked by a flexible peptide. Their small size (~27 kDa) facilitates production in microbial systems and enables better tissue penetration and access to cryptic epitopes, which is crucial for bacterial periplasmic proteins .

What are the recommended protocols for immunofluorescence using sohB antibodies?

For adherent bacterial samples, the following immunofluorescence protocol is recommended:

Fixation and Permeabilization:

• Fix bacterial cells with 4% paraformaldehyde for 15 minutes at room temperature

• Add 400 μL of 0.1% Triton X-100 in 1X PBS and incubate at room temperature for 15 minutes

• Wash three times with 500 μL of 1X PBS

Blocking and Immunostaining:

• Add 500 μL of 2% BSA in 1X PBS and incubate at room temperature for 60 minutes

• Add primary sohB antibody at the optimized concentration in 500 μL of 0.1% BSA and incubate for 3 hours at room temperature or overnight at 4°C

• Wash three times with 500 μL of 1X PBS

• Add fluorescent dye-labeled secondary antibody with appropriate counterstains in 500 μL of 0.1% BSA and incubate for 45 minutes at room temperature protected from light

• Wash three times with 500 μL of 1X PBS-T

Essential Controls:

• Control #1: Include samples without antibodies, only counterstains

• Control #2: Include samples with fluorescent dye-labeled secondary antibody only, without primary antibody to test for specificity

For optimal results, the concentration of counterstains, primary and secondary antibody dilutions, as well as fixation, blocking, and washing steps should be experimentally optimized for the specific bacterial strain and growth conditions.

How can I validate the specificity of a sohB antibody?

Rigorous validation of antibody specificity is critical for reliable research outcomes:

• Western Blot Analysis:

  • Confirm binding to a protein of the expected molecular weight (~37 kDa for mature sohB protein)

  • Compare wild-type E. coli lysates with sohB knockout or overexpression strains

  • Include purified recombinant sohB protein as a positive control

• Immunofluorescence Validation:

  • Perform parallel staining of wild-type and sohB knockout strains

  • Include secondary antibody-only controls to assess background staining

  • Observe expected periplasmic localization pattern

• Cross-Reactivity Testing:

  • Test reactivity against lysates from related bacterial species

  • Assess potential cross-reactivity with homologous proteases (e.g., HtrA/DegP)

• Antibody Absorption Tests:

  • Pre-incubate antibody with purified sohB protein to demonstrate specific binding

  • Observe elimination or significant reduction of signal after absorption

• Immunoprecipitation:

  • Confirm pull-down of the correct protein by mass spectrometry

  • Verify co-immunoprecipitation of known interaction partners

These validation steps ensure that experimental observations can be attributed specifically to the sohB protein rather than to non-specific binding or cross-reactivity with other bacterial components .

What are the optimal conditions for Western blotting using sohB antibodies?

For optimal Western blot results with sohB antibodies:

Sample Preparation:

• Carefully fractionate E. coli cells to isolate periplasmic proteins using osmotic shock or other gentle extraction methods

• Include protease inhibitors to prevent degradation

• Denature samples at 95°C for 5 minutes in loading buffer containing SDS and β-mercaptoethanol

Electrophoresis and Transfer:

• Use 10-12% SDS-PAGE gels for optimal resolution of the ~37 kDa sohB protein

• Transfer to PVDF membranes at 100V for 1 hour or 30V overnight in cold transfer buffer

• Verify transfer efficiency with reversible staining (Ponceau S)

Antibody Incubation:

• Block membranes with 5% non-fat milk or BSA in TBST for 1 hour at room temperature

• Dilute primary sohB antibody according to manufacturer recommendations (typically 1:1000-1:5000)

• Incubate with primary antibody overnight at 4°C with gentle rocking

• Wash 3 × 10 minutes with TBST

• Incubate with appropriate HRP-conjugated secondary antibody (1:5000-1:10000) for 1 hour at room temperature

• Wash 3 × 10 minutes with TBST

Detection and Controls:

• Use enhanced chemiluminescence (ECL) for detection

• Include wild-type and sohB knockout controls

• Include positive control (purified recombinant sohB)

• Consider loading controls appropriate for periplasmic proteins

These conditions should be optimized for each specific antibody and experimental system to achieve the best signal-to-noise ratio and reproducibility.

How should I interpret variations in sohB expression under different bacterial stress conditions?

When analyzing sohB expression patterns:

• Establish baseline expression:

  • Determine normal expression levels under standard growth conditions

  • Consider growth phase-dependent variations

• Stress response analysis:

  • Compare expression profiles under different stressors (temperature, pH, osmotic stress)

  • Note that sohB expression may be induced by excess nitrate, polyethylene glycol, NaCl, H₂O₂, and salicylic acid

• Kinetic considerations:

  • Track expression changes over time to distinguish early vs. late stress responses

  • Consider both transcriptional and post-translational regulation

• Functional redundancy:

  • Analyze parallel expression of related proteases (e.g., HtrA/DegP)

  • Interpret sohB upregulation in context of the broader stress response network

• Correlation with phenotype:

  • Link expression changes to bacterial survival, growth rates, or stress resistance

  • Consider compensatory mechanisms when interpreting knockout phenotypes

When evaluating immunoblot or immunofluorescence data quantitatively, ensure appropriate statistical analysis (e.g., multiple biological replicates, appropriate statistical tests) and normalization to account for variations in cell density and loading controls.

What controls are essential when analyzing data from experiments using sohB antibodies?

Robust experimental design requires multiple controls:

For antibody validation, it's particularly important to compare the staining pattern between wild-type bacteria and a sohB knockout strain. Additionally, controls examining cross-reactivity with other periplasmic proteases should be included to ensure signal specificity .

How can I compare results from different sohB antibody clones or detection methods?

When comparing data from different antibody clones or detection methods:

• Standardization approaches:

  • Use purified recombinant sohB protein as a common reference standard

  • Normalize signals to known concentration standards

  • Express results as relative changes rather than absolute values when using different antibodies

• Cross-validation strategies:

  • Confirm key findings with orthogonal methods (e.g., mass spectrometry)

  • Use multiple antibody clones targeting different epitopes

  • Complement antibody detection with genetic approaches (e.g., tagged protein expression)

• Quantitative considerations:

  • Account for differences in antibody affinity when comparing signal intensities

  • Consider developing correction factors based on direct comparison experiments

  • Use digital image analysis with appropriate background subtraction

• Statistical analysis:

  • Apply appropriate statistical tests to determine significance of differences

  • Consider power analysis to ensure adequate sample size

  • Report confidence intervals along with means/medians

To enable proper comparison, maintain detailed records of antibody characteristics (clone, lot, dilution), detection methods, image acquisition settings, and data processing steps.

How can computational approaches improve sohB antibody design?

Modern computational methods offer powerful approaches to antibody engineering:

• Structure-based design:

  • Predict sohB protein structure to identify accessible epitopes

  • Use molecular dynamics simulations to optimize antibody-antigen interactions

  • Apply in silico alanine scanning to identify critical binding residues

• Deep learning approaches:

  • Generate novel antibody sequences using generative adversarial networks (GANs)

  • Recent research demonstrates successful generation of 100,000 variable region sequences with high medicine-likeness (≥90th percentile) and humanness (≥90%)

  • Experimental validation shows these computationally designed antibodies exhibit high expression, monomer content, and thermal stability

• Active learning strategies:

  • Implement iterative cycles of computational prediction and experimental validation

  • Research shows active learning can reduce the number of required antigen mutant variants by up to 35%

  • This approach speeds up the learning process by 28 steps compared to random baseline methods

• Library design and screening:

  • Generate diverse antibody libraries with desired biophysical properties

  • Apply computational filters to prioritize candidates for experimental testing

  • Experimental results show computationally designed antibodies can achieve expression yields of 7.5-32.7 mg/L and monomer percentages of 91.4-98.6% after purification

The table below summarizes experimental results from computationally designed antibodies compared to a control antibody (trastuzumab):

These data demonstrate that computationally designed antibodies can achieve performance comparable to or better than clinically established antibodies .

What are the latest advances in mapping and engineering antibody-antigen interaction landscapes?

Recent methodological advances have revolutionized our understanding of antibody-antigen interactions:

• High-throughput mapping approaches:

  • Single-Protein Interaction Detection (SPID) platform enables systematic mapping of antibody-antigen interaction landscapes with unprecedented depth and speed

  • This approach rivals the precision of methods like Surface Plasmon Resonance (SPR) and Bio-Layer Interferometry (BLI) while significantly boosting throughput

• CDR engineering strategies:

  • Systematic modification of Complementarity Determining Regions (CDRs), particularly CDRH3, which exhibits the highest diversity and plays a key role in antigen recognition

  • Analysis of CDRH3 sequences can serve as a B cell clonal "barcode" for tracking antibody development and maturation

• Machine learning integration:

  • BetterBodies approach combines Variational Autoencoders (VAEs) with offline Reinforcement Learning (RL) guided latent diffusion

  • This method generates novel sets of antibody CDRH3 sequences with improved binding affinity properties

• Biophysical property optimization:

  • Development of contrastive loss approaches to reflect biophysical properties in the VAE latent space

  • Implementation of Q-function based filtering to enhance binding affinity of generated sequences

  • Experimental validation using the Absolut! simulator demonstrates improved binding affinity to targets like SARS-CoV spike receptor-binding domain

• Library-on-library approaches:

  • Screening many antigens against many antibodies to identify specific interacting pairs

  • Machine learning models can predict target binding by analyzing these many-to-many relationships

These advances enable researchers to develop antibodies with finely-tuned affinities and expand the druggable antigen space to include targets that are refractory to conventional antibody discovery methods.

How can I optimize first-in-human (FIH) study designs for antibodies against bacterial targets?

When designing first-in-human studies for antibody therapeutics targeting bacterial antigens:

• Population pharmacokinetics (popPK) modeling:

  • Use the 2-compartment model with first-order elimination for antibody PK modeling

  • Typical parameter estimates for systemic clearance: ~0.20 L/day (with 31% intersubject variability)

  • Typical central volume of distribution: ~3.6 L (with 34% intersubject variability)

• Sampling design optimization:

  • Rich sampling designs (22 samples/subject) provide the most precise estimates but increase subject burden

  • Optimal designs (10 samples/subject) balance precision with practical considerations

  • Minimal designs (5 samples/subject) may have increased bias and between-trial variability

• Route of administration considerations:

  • For intravenous (IV) administration: Consider doses within 1-700 mg range based on previous studies

  • For subcutaneous (SC) administration: Consider doses within 2.1-700 mg range based on previous studies

• Antibody isotype selection:

  • Both IgG1 and IgG2 isotypes have been successfully used in clinical studies

  • Selection should be based on desired effector functions and target biology

The table below summarizes dosing ranges used in previous first-in-human studies for monoclonal antibodies:

These parameters can guide the design of efficient first-in-human studies for antibodies targeting bacterial proteins like sohB .

What role does Toll-like receptor 9 (TLR9) signaling play in antibody responses to bacterial antigens?

TLR9 signaling has important implications for antibody responses to bacterial antigens:

Understanding these interactions is crucial when developing and evaluating antibodies against bacterial targets, including periplasmic proteases like sohB .

How can nanopore technology enhance antibody-based detection of bacterial proteins?

Solid-state nanopore technology offers innovative approaches for antibody-based detection:

• Single-molecule detection capabilities:

  • Solid-state pores fabricated on substrates <50 nm thick can detect analytes individually

  • Different pore diameters enable detection of various biomolecules: few nm pores for DNA/RNA/proteins, 100 nm pores for viruses, and μm pores for bacteria

• Immunoreaction integration:

  • Combining immunoreactions with solid-state pores enables efficient testing with high specificity and sensitivity

  • This hybrid approach has achieved detection limits as low as 24.9 fM for protein antigens in 30 minutes

• Quantitative analysis advantages:

  • Precise analysis of mixed populations with different bead sizes with error rates up to 4.7%

  • Suitable for rapid, easy-to-use tests with lower detection limits than conventional immunoassays

• Applications for bacterial protein detection:

  • Could be adapted for detection of periplasmic bacterial proteins like sohB

  • Potential for point-of-care testing in clinical or field settings

  • Enables rapid development of assays without requiring chemical modification of the solid-state pore

• Technical considerations:

  • Requires optimizing antibody conjugation to beads or surfaces

  • May need customization of pore sizes based on target protein and antibody complex dimensions

  • Signal processing algorithms must be adapted for specific antigen-antibody systems

This technology represents a promising frontier for ultra-sensitive detection of bacterial proteins with potential applications in both research and diagnostic contexts .